Screening for Bacterial Vaginosis in Pregnancy, Table 2. Overview of high-risk studies

You Are Here: AHRQ Archive Home > Screening for Bacterial Vaginosis in Pregnancy: Summary of the Evidence

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 2. Overview of high-risk studies¹

Factor	Carey(39)	McDonald(38)	Hauth(37)	Morales(36)	Vermuelen(35)
PTD <37 weeks, placebo	23%	35%	57%	39%
GA (wk) at treatment	16-23	24	22-24	13-20	26
Treatment	Oral metronidazole 2 g, repeat @ 48 hr	Oral metronidazole 400 bid, 2 d	Oral metronidazole 250 mg tid, 7 days, plus oral erythromycin 333 mg tid, 14 d	Oral metronidazole 250 mg tid, 7 d	Clindamycin 2% vaginal cream daily, 7 d
Second treatment	All, 24-29 wk	If positive test, 4 wk post-treatment	If positive test, at 28 wk	No second treatment	All, 32 wk

^[1] PTD, preterm delivery; GA, gestational age.

Return to Document

The information on this page is archived and provided for reference purposes only.

Table 2. Overview of high-risk studies1

Table 2. Overview of high-risk studies¹